Every DEF 14A that FibroBiologics, Inc. (FBLG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow FBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBLG filings page.
FibroBiologics, Inc. is calling a virtual special meeting on September 17, 2026 to seek stockholder approval, under Nasdaq Listing Rule 5635(d), for the potential issuance of up to 8,163,266 shares of common stock upon exercise of outstanding Warrants under a June 25, 2026 securities purchase agreement and up to 285,714 shares upon exercise of Placement Agent Warrants.
These Warrants carry exercise prices of $0.735 and $0.9188 per share; if fully exercised they would yield approximately $6.0 million and $263 thousand in gross proceeds, respectively, but would dilute existing holders through new common shares.
As of July 20, 2026 there were 6,658,193 common shares outstanding and 125 super-voting Series C Preferred shares, each with 13,000 votes. The Board holds an irrevocable proxy over these preferred shares and plans to cast 1,625,000 votes, about 20% of eligible votes, in favor of the proposal. If approval is not obtained, the company states it cannot issue shares above Nasdaq’s 20% threshold under these Warrants and may owe liquidated damages, potentially straining liquidity and requiring emergency financing, while repeated stockholder meetings every 90 days would add legal cost and management distraction.
FibroBiologics, Inc. is asking stockholders to vote at its June 22, 2026 virtual annual meeting on director elections, auditor ratification, a significant warrant-related share issuance and a new equity incentive plan.
Proposal 3 seeks approval, for Nasdaq Listing Rule 5635(d) purposes, for up to 2,272,728 shares of common stock from March 2026 investor warrants and up to 159,091 shares from placement agent warrants, both tied to a prior financing. Proposal 4 would adopt the 2026 Equity and Incentive Compensation Plan with 2,000,000 new shares plus 339,199 remaining from the 2022 plan and an annual “evergreen” increase of up to 4% of shares outstanding through 2036, which could raise fully diluted overhang from 10.7% to 33.5%.
The company also outlines voting mechanics, including 5,208,915 common shares (one vote each) and 125 shares of Series C Preferred Stock with 13,000 votes per share, and the Board’s plan to cast 1,625,000 votes (about 24% of total voting power) in favor of all proposals under an irrevocable proxy.
FibroBiologics, Inc. is asking stockholders to approve several capital actions at a virtual special meeting on February 20, 2026. The centerpiece is a reverse stock split of its common and preferred stock at a ratio between 1‑for‑5 and 1‑for‑30, to be implemented at the Board’s discretion within one year, primarily to help the company regain compliance with Nasdaq’s $1.00 minimum bid price and other listing standards.
As of December 26, 2025, the company had 66,519,722 common shares outstanding and 2,500 Series C preferred shares, each with 13,000 votes; the Board will vote 32,500,000 of these preferred votes (32.8% of eligible votes) in favor of all proposals. Stockholders are also being asked to approve, under Nasdaq Listing Rule 5635(d), the potential issuance of up to 12,110,203 shares on exercise of November 18 warrants, up to 4,791,047 shares related to November 24 warrants and placement agent warrants, and up to 5,593,184 shares related to December warrants and placement agent warrants, plus a standard adjournment proposal.
FibroBiologics, Inc. is calling a virtual special meeting on February 20, 2026 to ask stockholders to approve a reverse stock split and several stock issuance proposals tied to recent financings. The reverse split would combine between 5 and 30 shares into one, at a ratio later chosen by the Board, to help the company regain compliance with Nasdaq’s $1.00 minimum bid price and address delisting risk. As of December 26, 2025, there were 66,519,722 common shares and 2,500 Series C preferred shares outstanding, with the Series C carrying 32,500,000 votes, or 32.8% of total voting power under an irrevocable proxy held by the Board. Stockholders are also being asked to approve, under Nasdaq Listing Rule 5635(d), the issuance of up to 12,110,203, 4,477,614 plus 313,433, and 5,227,275 plus 365,909 common shares upon exercise of low-priced warrants from November and December 2025 offerings, which could both provide several million dollars of cash proceeds and meaningfully dilute existing ownership.